Inactive

Background: The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which... Background: The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: August 2020: The following drug classes/subclass and newly approved agents will be reviewed: ADHD Agents, SUB CLASS: Stimulants – Aptensio XR Endocrine Agents Miscellaneous, SUB CLASS: N/A – Bynfezia Luteinizing Hormone-Releasing Hormone Agonists-Antagonists , SUB CLASS: N/A – Fensolvi Corticosteroids Immune Modulators, SUB CLASS: High Potency – Halog Pain Agents, SUB CLASS: Pain Topical – Licart Antilipidemics-1, SUB CLASS: N/A – Nexlizet Calcium Channel Blocking Agents, SUB CLASS: N/A – Nymalize Luteinizing Hormone-Releasing Hormone Agonists-Antagonists, SUB CLASS: N/A – Oriahnn Contraceptive Agents, SUB CLASS: Miscellaneous – Phexxi Oncological Agents, SUB CLASS: N/A – Qinlock Oncological Agents, SUB CLASS: Lung Cancer – Retevmo Oncological Agents, SUB CLASS: Lung Cancer – Tabrecta Multiple Sclerosis Agents, SUB CLASS: Oral Miscellaneous – Zeposia RFQ: The RFQ, including UF BPA and UF ADP appendices are attached herein. Pre-proposal teleconference is on June 17, 2020 details are stated in Part 2.5. Pre-proposal teleconference, contact RFQ Point of Contact (POC) for agenda and dial-in information. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC stated in Part 2.3, no later than the date stated in Part 2.4. POCs: Part 2.3 of the RFQ.